Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 48,995,576
  • Shares Outstanding, K 259,428
  • Annual Sales, $ 6,206 M
  • Annual Income, $ 2,712 M
  • 60-Month Beta 0.63
  • Price/Sales 7.88
  • Price/Cash Flow 20.69
  • Price/Book 5.59
Trade VRTX with:

Options Overview

Details
  • Implied Volatility 27.16%
  • Historical Volatility 17.83%
  • IV Percentile 18%
  • IV Rank 18.37%
  • IV High 51.43% on 05/27/21
  • IV Low 21.70% on 09/07/21
  • Put/Call Vol Ratio 1.95
  • Today's Volume 2,199
  • Volume Avg (30-Day) 2,059
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 35,667
  • Open Int (30-Day) 36,650

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 2.70
  • Number of Estimates 7
  • High Estimate 2.88
  • Low Estimate 2.29
  • Prior Year 2.36
  • Growth Rate Est. (year over year) +14.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
185.44 +0.90%
on 09/16/21
202.77 -7.73%
on 08/27/21
-3.87 (-2.03%)
since 08/16/21
3-Month
185.32 +0.96%
on 06/22/21
204.88 -8.68%
on 07/28/21
-0.39 (-0.21%)
since 06/16/21
52-Week
185.32 +0.96%
on 06/22/21
280.99 -33.41%
on 10/13/20
-80.45 (-30.07%)
since 09/16/20

Most Recent Stories

More News
Here's Why You Should Retain QIAGEN (QGEN) Stock For Now

Investors are optimistic about QIAGEN (QGEN) owing to impressive sales of diagnostic solutions and strong international growth.

VRTX : 187.10 (-0.93%)
QGEN : 54.15 (+1.23%)
MRNA : 440.65 (+1.42%)
HZNP : 107.95 (+1.77%)
Sickle Cell Disease Drugs Market: Industry Outlook, Classification, Demand, Regional Analysis and Forecast to 2030

Research Nester released a report titled which delivers a detailed overview of the global sickle cell disease drugs market in terms of market segmentation by treatment type, disease type, end-user, and...

EMMA : 1.5800 (+9.72%)
GBT : 26.35 (+1.46%)
SIOX : 2.24 (+1.36%)
IMRA : 4.47 (+3.00%)
BLUE : 17.68 (-0.67%)
VRTX : 187.10 (-0.93%)
5 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock Now

New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups should drive sales of Vertex's (VRTX) cystic fibrosis drug, Trikafta sales higher.

VRTX : 187.10 (-0.93%)
MRNA : 440.65 (+1.42%)
CRSP : 117.42 (+0.14%)
KYMR : 64.90 (-0.14%)
ObsEva (OBSV) Files NDA for Linzagolix to Treat Uterine Fibroids

ObsEva (OBSV) submits an NDA to the FDA for linzagolix as a potential treatment for uterine fibroids.

REGN : 653.18 (+0.18%)
VRTX : 187.10 (-0.93%)
ABBV : 108.08 (+0.29%)
OBSV : 3.08 (+0.65%)
Emergent (EBS) Inks COVID-19 Manufacturing Deal With Providence

Emergent (EBS) is set to provide manufacturing services for doses of Providence Therapeutics' COVID-19 vaccine candidate as well as for its bulk drug substance.

AZN : 56.60 (+0.27%)
JNJ : 165.22 (-0.12%)
VRTX : 187.10 (-0.93%)
EBS : 57.47 (+0.56%)
Axsome's (AXSM) Migraine Drug AXS-07 NDA Gets FDA Acceptance

Axsome (AXSM) is seeking approval for its key pipeline candidate, AXS-07, as a potential acute treatment for migraine.

PFE : 44.47 (-0.67%)
VRTX : 187.10 (-0.93%)
AXSM : 28.53 (+2.92%)
HRMY : 37.10 (+2.06%)
Alnylam (ALNY) Files MAA to EMA for Rare Disease Drug Vutrisiran

Alnylam (ALNY) submits a marketing authorization application to the EMA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

ALNY : 190.20 (+1.45%)
VRTX : 187.10 (-0.93%)
CRVS : 2.26 (-1.31%)
SPRO : 19.05 (+2.81%)
Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on Wednesday, September 15th, 2021...

VRTX : 187.10 (-0.93%)
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $188.57 in the latest trading session, marking a +0.26% move from the prior day.

VRTX : 187.10 (-0.93%)
What Makes Vertex (VRTX) a New Strong Buy Stock

Vertex (VRTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

VRTX : 187.10 (-0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs...

See More

Key Turning Points

3rd Resistance Point 193.37
2nd Resistance Point 191.45
1st Resistance Point 189.28
Last Price 187.10
1st Support Level 185.18
2nd Support Level 183.26
3rd Support Level 181.09

See More

52-Week High 280.99
Fibonacci 61.8% 244.45
Fibonacci 50% 233.16
Fibonacci 38.2% 221.87
Last Price 187.10
52-Week Low 185.32

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar